Could ketamine be the key to easing sickle cell pain in kids?
NCT ID NCT07369024
First seen Jun 24, 2026 · Last updated Sep 03, 2026 · Updated 3 times
Summary
This study is testing whether a low dose of ketamine, given alongside standard pain medicine, can better control severe pain from sickle cell disease in children and young adults aged 5 to 20. Participants will receive either ketamine or a placebo infusion, and researchers will measure how much opioid pain medicine they need and how quickly their pain improves. The goal is to find a safer, more effective way to manage sickle cell pain crises.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ketamine
- What this could lead to
- If it works, this could offer a safer, more effective way to manage severe sickle cell pain in young people, potentially reducing reliance on opioids.
- What could go wrong
- This is a Phase 2 trial with only 120 participants, so results are preliminary. Ketamine may not provide additional pain relief and could cause side effects like dizziness or hallucinations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
5 to 20 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Between the ages 5-20 years * Diagnosed sickle cell disease. Homozygous (HbSS) or heterozygous (HbSC, HbSBetaThal Plus or Zero) will be included. * Presenting with VOE pain, requiring IV pain medication. * First dose of analgesic medication is given before patient approached for participation in the study. * Primary language is English or Spanish * Adult individual or parent/legal guardian is able and willing to provide informed consent. For individuals 7 to 17 years of age, assent must also be provided when cognitively possible. Exclusion Criteria: * Sickle cell trait only * Patients whose primary language is other than English or Spanish * Pain attributed to causes other than VOE * Not requiring IV for pain treatment * No analgesic (e.g. opiate) is given before approach for study participation due to any reason, including problem with IV access. * Oxygen saturation \< 90% on room air * History of prior adverse reaction to ketamine * History of hypertension - Patients with active/uncontrolled hypertension defined as systolic 140 mmHg over diastolic of 90 mmHg will be excluded from participation in the study. If hypertension is controlled and at the time of enrollment, systolic and diastolic thresholds of 140 mmHg and 90 mmHg respectively are not exceeded, patient may be included in the study * History of significant or uncontrolled cardiovascular disease, liver disease, kidney disease, and thyroid disease * Patients with evidence of increased intracranial pressure * Patients with elevated intraocular pressure * Patients with acute mania or history of bipolar disorder with manic episodes, history of hallucinations or paranoia secondary to previously diagnosed psychiatric condition * Pregnant or potentially pregnant patients per patient report. All patients of childbearing potential will undergo pregnancy testing prior to enrollment (as part of clinical care), and if positive, will be excluded. * Elevated liver enzymes (alkaline phosphatase, ALT, AST, bilirubin) as sign of hepatic disfunction if the laboratory results are available prior to study participation * Patients who appear intoxicated on any substance. * Patients who are wards of the state or prisoners as defined by DHS * Patients who are not deemed to be competent to provide consent or assent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ketamine infusion are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Harbor UCLA Medical Center
RECRUITINGTorrance, California, 90509, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sickle cell clues to diabetes risk hidden in DNA
- Can adding common pain drugs reduce morphine needs in sickle cell crises?
- New drug tested to curb pain after liver surgery
- Two simple tweaks may cut pain after appendix surgery
- Nerve blocks put to the test for chest tube pain
- Gene editing offers hope for a One-Time sickle cell cure